Scientific article

Hépatite D:oubliée mais pas disparue

Other titleHepatitis D: forgotten but not gone
Published inRevue médicale suisse, vol. 6, no. 261, p. 1656-1659
Publication date2010

Hepatitis D virus (HDV) is a subviral agent which depends on the envelope proteins (HBsAg) of hepatitis B virus (HBV). Therefore, hepatitis D is observed only in patients infected with HBV. Chronic hepatitis D is the least frequent albeit most severe form of chronic viral hepatitis. A resurgence of chronic hepatitis D has been observed in Northern and Central Europe, mainly due to immigration of patients from regions with high prevalence. Every HBsAg-positive patient should be screened for concurrent HDV infection. Standard treatment consists of pegylated interferon-alpha for at least one year. Sustained virological response rates are approximately 20%. Liver transplantation should be considered in patients with advanced cirrhosis or limited hepatocellular carcinoma. Preventive measures for hepatitis D are the same as for hepatitis B.

  • Antiviral Agents/therapeutic use
  • European Union/statistics & numerical data
  • Hepatitis B/complications
  • *Hepatitis D/diagnosis/epidemiology/therapy
  • Hepatitis D, Chronic
  • Hepatitis Delta Virus/isolation & purification
  • Humans
  • Interferon-alpha/therapeutic use
  • Liver Transplantation
  • Polyethylene Glycols/therapeutic use
  • Prevalence
  • Recombinant Proteins
  • World Health
Citation (ISO format)
MORADPOUR, Darius, NEGRO, Francesco. Hépatite D:oubliée mais pas disparue. In: Revue médicale suisse, 2010, vol. 6, n° 261, p. 1656–1659.
ISSN of the journal1660-9379

Technical informations

Creation05/22/2012 3:15:35 PM
First validation05/22/2012 3:15:35 PM
Update time03/14/2023 5:30:01 PM
Status update03/14/2023 5:30:01 PM
Last indexation01/15/2024 11:38:36 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack